Hybio Pharmaceutical (300199.SZ): Carboprost Tromethamine Injection has obtained a drug registration certificate.

Hybio Pharmaceutical (300199.SZ) announced that its wholly-owned subsidiary, Gansu Chengji Biopharmaceutical Co., Ltd. (hereinafter referred to as "Chengji Pharmaceutical"), has recently received the "Drug Registration Certificate" for Carboprost Tromethamine Injection issued by the National Medical Products Administration. Carboprost Tromethamine Injection is a prostaglandin drug primarily used for the treatment of postpartum hemorrhage due to uterine atony, and it is commonly used in clinical settings as a postpartum hemostatic agent. The receipt of the drug registration certificate for Carboprost Tromethamine Injection enriches the product pipeline of the company and its subsidiary Chengji Pharmaceutical in the field of obstetrics and gynecology, enhancing the company's competitiveness in the market for gynecological hemostatic drugs. The company will promptly advance the market launch and sales of this product in accordance with relevant requirements.